Skip to main content

Mark Baldry

Equibles does not estimate personal net worth.

About Mark Baldry

X4 Pharmaceuticals, Inc reported in an 8-K filed September 17, 2025 that Mark Baldry was terminated as Chief Commercial Officer, effective September 15, 2025. The proxy statement of X4 Pharmaceuticals, Inc reports total compensation of $1,171,703 for Mark Baldry in fiscal 2024, including a base salary of $475,000. Mark Baldry has spoken on 5 earnings calls across 1 company, most recently for X4 Pharmaceuticals, Inc on May 1, 2025. The companies whose calls Mark Baldry spoke on are classified in the Healthcare sector.

“on September 15, 2025, the Board of Directors (the "Board") determined to terminate the employment of Dr. Mary DiBiase, the Company's Chief Operating Officer, Mark Baldry, the Company's Chief Commercial Officer, and Natasha Thoren, the Company's Chief Legal & Compliance Officer, in each case effective as of September 15, 2025.”
X4 Pharmaceuticals, Inc Form 8-K, filed September 17, 2025 · Read the filing

Mark Baldry on recent calls

“Ted, I was just going to say we're continuing to build our insights into the CN market itself and actually just completed a large survey with about 95 US physicians who treat chronic neutropenia.”
CCO, X4 Pharmaceuticals, Inc Q1 FY2025 Earnings Call ·
“You’re right, we’re laser-focused right now on raising disease awareness and driving screening for WHIM and presenting XOLREMDI as a treatment that has proven to work in WHIM.”
CCO, X4 Pharmaceuticals, Inc Q3 FY2024 Earnings Call ·
“Ted, we had a terrific meeting at CIS in Minneapolis last week. We debuted our now approved booth, and there was lots of excitement and enthusiasm around there.”
CCO, X4 Pharmaceuticals, Inc Q1 FY2024 Earnings Call ·
“And what’s been interesting is through our disease awareness campaign, we’ve really seen that light bulb go on as we highlight the fact that these patients can present very differently.”
CCO, X4 Pharmaceuticals, Inc Q4 FY2023 Earnings Call ·
“We thought it would be helpful to start by highlighting some of the ways that we’ve been engaging with the WHIM community, developing an understanding of the market landscape and establishing a foundation for a successful introduction of mavorixafor to physicians, patients, and payers.”
CCO, X4 Pharmaceuticals, Inc Q3 FY2023 Earnings Call ·

Affiliation history

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 X4 Pharmaceuticals, Inc (XFOR) $475,000 $1,171,703

Recent activity